A blocking peptide, TAT‐PEP, specifically abrogating ATAD3A phosphorylation, results in elevated cell death by preventing doxorubicin‐induced senescence, thus leading to enhanced tumor sensitivity to chemotherapy. Here, ATAD3A is linked to neoplasm.